

Sophiris Bio Inc (SPHS) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/S0A479AEF4BEN.html>

Date: September 2020

Pages: 43

Price: US\$ 125.00 (Single User License)

ID: S0A479AEF4BEN

Abstracts

Sophiris Bio Inc (SPHS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Sophiris Bio Inc (Sophiris) is a biopharmaceutical company that focuses on the research and development of products for treating urological diseases. The company's lead pipeline product is Topsalysin (PRX302), which is being developed for the treatment of localized low to intermediate prostate cancer, as well as for the treatment of lower urinary tract symptoms of enlarged prostate or benign prostatic hyperplasia (BPH). It is a modified recombinant protein that is delivered through ultrasound-guided injection directly into the prostate. The company primarily operates in the US and has collaboration and license agreements with UVIC Industry Partnerships Inc, The Johns Hopkins University and Kissei Pharmaceutical Co., Ltd for the development and commercialization of its pipeline product. Sophiris is headquartered in La Jolla, California, the US.

Sophiris Bio Inc Key Recent Developments

May 18,2020: Sophiris Bio to shut down operations

Mar 10,2020: Sophiris Bio announces Nasdaq delisting

Nov 07,2019: Sophiris Bio reports third quarter 2019 financial results and recent corporate highlights

Aug 09,2019: Sophiris Bio reports second quarter 2019 financial results and recent

corporate highlights

May 09,2019: Sophiris Bio reports first quarter 2019 financial results

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Sophiris Bio Inc - Key Facts
Sophiris Bio Inc - Key Employees
Sophiris Bio Inc - Key Employee Biographies
Sophiris Bio Inc - Major Products and Services
Sophiris Bio Inc - History
Sophiris Bio Inc - Company Statement
Sophiris Bio Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Sophiris Bio Inc - Business Description
Sophiris Bio Inc - SWOT Analysis
SWOT Analysis - Overview
Sophiris Bio Inc - Strengths
Sophiris Bio Inc - Weaknesses
Sophiris Bio Inc - Opportunities
Sophiris Bio Inc - Threats
Sophiris Bio Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Sophiris Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Sophiris Bio Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020

Sophiris Bio Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

May 18, 2020: Sophiris Bio to shut down operations

Mar 10, 2020: Sophiris Bio announces Nasdaq delisting

Nov 07, 2019: Sophiris Bio reports third quarter 2019 financial results and recent corporate highlights

Aug 09, 2019: Sophiris Bio reports second quarter 2019 financial results and recent corporate highlights

May 09, 2019: Sophiris Bio reports first quarter 2019 financial results

Mar 13, 2019: Sophiris Bio reports fourth quarter 2018 and year-end financial results and recent corporate highlights

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Sophiris Bio Inc, Key Facts
Sophiris Bio Inc, Key Employees
Sophiris Bio Inc, Key Employee Biographies
Sophiris Bio Inc, Major Products and Services
Sophiris Bio Inc, History
Sophiris Bio Inc, Subsidiaries
Sophiris Bio Inc, Key Competitors
Sophiris Bio Inc, Ratios based on current share price
Sophiris Bio Inc, Annual Ratios
Sophiris Bio Inc, Annual Ratios (Cont...1)
Sophiris Bio Inc, Interim Ratios
Sophiris Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Sophiris Bio Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Sophiris Bio Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Sophiris Bio Inc, Performance Chart (2014 - 2018)

Sophiris Bio Inc, Ratio Charts

Sophiris Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020

Sophiris Bio Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

COMPANIES MENTIONED

Procept Biorobotics Inc

Pfizer Inc

Nymox Pharmaceutical Corp

NXThera Inc

Lipocine Inc

Light Sciences Oncology Inc

Astellas Pharma US Inc

Allergan Finance LLC

I would like to order

Product name: Sophiris Bio Inc (SPHS) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/S0A479AEF4BEN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S0A479AEF4BEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970